Charlty rng18trallon nUmt￿r 1141310
CURE CANCER
UCL CANCER INSTITUTE
TRUSTEES. REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

CURE CANCER @ UCL CANCER INSTITUTE
LEGAL AND ADMINISTrATIVE INFORMATION
S 8agho
S Hamllton
N Hamllton
J Maryolln MBE
S Sampwn FCA
¢haTRy number
1141310
Prlnclp•l addra••
Pltt Ho
120 Baker Streat
London
W1U 6TU
Ind•pond•nt •xamln•r
Unit 101. Flr8t Floor
CeTrMntes House
&9 He8dstone Road
HA11PD
Bankw8
Nat￿81 Bank PIC
9 The Broath
Stsnmore
Mlddle8ex
HA7 4DA

CURE CANCER @ UCL CANCER INSTMJTE
cop¥rENTS
7-11

CURE CANCER @ UCL CANCER INSTITUTE
TRUSTEE8' REPORT
FOR THE YEAR ENDED 31 AIARCH 2025
finandal sl8tement8 and Ihg Charit￿8 tgo¥effdng d0￿M￿l, ts Ctrorftles Act 2011 and "Accwnllng
and Reporlng ty Charltleg: Slotemert of Recommffidad Prndi¢* ￿l¢able to Charl￿ preparlng theEr acco￿ In
ac£4)rdance wllh the Finandd Rtyrydng S￿#l￿d in Ihe UK and Rep￿1* of Irdarrfl IFRS
102)" (affecll¥o 1 January 2019).
ObJ•dlw and a¢tlvltles
Cure Cancer
UCL e￿¥ts to fuTrY rnsearth into P*TrHry]gkn's Lymp1￿￿. The tharity foundad by
Mrs Sandra Hamkn and 18 swwrted by Its Patron8: Prof8s8or knthony Goldstone. CBE (University Cdtego
HospStal, Lond¢MI; Mrkndrns Ittrchls (Head ofts Cancer Unl( 88Th￿t Germl Fwld): Ractsl St•M￿. togother
with a large and enthuslastic repres￿￿￿4 a *ldo ofages and ex￿1￿nCe.
Durfng the IhwKI81 >*ar. Ilwough a (rf fvndr*lry and donath. the ch8rty ralwj a trjlal of
£39.723.
Induded. butwag not Its)th￿ to..
Fundralalng e¥•Nts
. Amual Clarwnt E¥￿Ir￿j IK*ted at ts V* Hotsl, Elstre

CURE CANCER
UCL CANCER INSTITUTE
TRU8TEE8' REPORT (COPrnNUED)
FOR THE YEAR ENDED 31 AIARCH 2025
FIn•nCl￿ rnvl•w
Publk B•n•fit 8t•l•m•rt
Tho th olcum Canc•r Q UCL ljenofits Iho ty.
outcom68 4nd supAval rale•.
pthnl• and th*famlllM bath lo• •MI ￿0bally.
. EnG8olng tho ujmfflunlty In fundralslng of c4M￿r few1￿h, onc(¥mlnll
Idar publk parUd￿lIan tn c*wltth 814¥AyL
In thkn way. tru•ts¢• •rn •8ll•lknd ttwt th• d•l¥w dDtrand publk ben•llL
Acknowhdpmont•
Wg extend our SIn￿rn Ihonk8 to ou cA)mmltto• dorKX•, •KI wJpsyJtsrn th*￿ ho¥0 ￿ntrIbutOd
Iholr tlme. oXPert18e, and g•n8ro8ty thr(￿gh￿rt Iho yew.
C•notttuU•n
Th• ¢h*itys govwnlng d0￿mont l• ItsTnJ•t 0•gd dI￿j 2011 r<•J •mond•d ￿ 27 Octob•r2011.
The tru￿•08 a•r￿ed duty th• and w) toth• d•1• ollh ftmndal *•tom•nts vMr•:
S Baghgrf
S Hamtii
N Hamltton
J Margolin MBE
S Sampson FCA
the Trust Deed.

CURE CANCER
UCL CANCER INSTITUTE
TRUSTEE8' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Tho Tru8lwo' rolkn wa• ooprovod by the Board ofThi8toM.
S Hamllton
27 Auouat 2025

CURE CANCER
UCL CANCER INSTITUTE
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF CURE CANCER
UCL CANCER INSTITUTE
I report to tho trustees on my examlnatton of thg fmancial 81at8Fn8nts d Cur• Cancer
tharfty) forthe year8nded 31 March 2026.
UCL canc￿ Institute (the
R68ponslbllltl•g ayrfl bas1• of r•wrt
As the tNstees of th8 charity you aro ro¥ponslble for weparakn of tho fjnand818tatements In oo>xdarth with
the requlrements of thg ChartitOB Acl 2011 (the 2011 Act).
I report In r6BpaL* of rny oxamlnakn Lrf th8 charfty8 finan1￿￿ 8tatem6nts cavrfed out undgr seL*lon 145 of th8 2011
ACL In carylng out my ex8mlnatlon I havo follcM*d all the aWl¢oble Dlro¢th)n$ glvon by the Charity Commlsthn
under 8acalon 145(5Xb) of the 2011 ACL
Indo￿ndon1 uamln•rf8 Statoment
Y¢)w att•ntlon Is drawn to the fact that tho tharlty ha8 prnpar•d Iln8nd81 statemgnts in a¢£ttd8￿ wllh knx)untlng
and Reporting by ChaTiUe5 preparfrvJ thelr a￿Ints In 8coJrdan¢* wth Ihe Flnanaal RepoTling Slandard apkllcable
In th& UK and Rspubllc of Irolar￿ (FRS 102> In pr&farenLX to thè Aecounting and Reporting by Chaiities: Statement
of Rw)mmended PractlGe IsBued on 1 P4>rll 2005 whid) is referrad to In thg gxtant regulattor￿ but ha8 been
l undersland that this h88 boen done In othr for IlnancAal 8tstanents to provtdo a true and fakvlew In acc)xdance
with GwwrallyA¢¢oPtod A¢o)unttsw Pract1￿ effectlve lor rep¢)rfing porlods bfjgln￿ng on or after 1 January 2015.
I havo ￿nPleted my examln811on. I confimi that matt6rs have Ixxne b my attontlon In ¢onn¢¢tim wlth tho
oxamlnatlon gfvlng mo cau8e to bellove Ihqt In any mat•rfal rospo¢t
a￿OuntIng rK¢rds worn ￿)t kept In respect of the charfty as roqyirod ty ge¢lion 130 ofthe 2011 A¢ *x
tha finan¢lal 8talomgnts do not accord with those records;
t￿ fln8ncLql Statements do not comply with Ihe eppllcabh requlrements concemlng th8 ft>mi ond ¢ontgnt of
acuunts Set out In the ChartUè8 {Ace4)unts and Reports) Regulations 2008 other than any requtr8menl that tr
actounts glve a Irue aNI lalrvwNwhich18 not a matter con8kl8red as part of an Independent oxamlna
I have no corum6 and ha￿ comg atyoss no othar matter8 In cx*nnodon th• •x8mlnatlon to *thlch attenlon
Should be In thts report in orderto enable a proper under8tandlng of the fin•na81 statgmorts to b8 rea¢1%￿.
Slgned:
SaTrJay Kumar Sah ACA FCCA
Unrt 101. Flr8t Floor
C8rv8nte8 H¢)U8e
&9 Headst￿ Road
Ham. HA11PD
Dated: 27 Auguot 2025

CURE CANCER @ UCL CANCER INSIITUTE
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025
Unro8trl¢tsd Unrn8trlGtod Re8trl¢tsd
fvnd&
fundB
2026
2024
DOr￿ljun8 and legade8
Charitable actiwuss
Inveslments
8.183
31.540
7,160
17.426
1.244
7,160
18,426
1,244
T¢>lal Incomo
25.830
26,830
CharSt8bl8 8CtlvlUes
1.ofK)
Not {wondliurnylncom• lorth• yoarf
Not movement In fund•
(5S.884)
20.248
Fund balon￿9 8t 1 Aprfl 2024
88,349
68.101
68.101
Fund balonco8 at 31 March 2025
32.665
88W9
88.349
The Statemert offinandal aclMll88 Ind￿908 am galM and1088•s recognbod In Iho ￿r.
I Incoma and eXpondI￿re dar￿ from conllnulNJ aclvlues.

CURE CANCER
UCL CANCER INSTrruTE
BALANCE SHEEr
ASAT31 AIARCH 2025
Deblors
Cash at bank and In haThl
187
33.478
87,519
89,809
Cr•dllorn: ￿￿￿nIS fallh¥ wlthln
e year
11
(1.01)0)
(1,460)
88.349
Incomo fund•
88,349
88,349
S H8mNton

CURE CANCER
UCL CANCER INSTITUTE
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Accountlng pollcl
Charfty Inhrmallon
Cur• Canc*r
UCL Can(*r In8tllut• Is a L*arlty regl8ter•d In Engl•nd. reglstratlon numbor 1141310. Its
prlndpal offl¢8 Ss Pltt House, 120 Baker Street, London. W1U 6TU.
1.1 A¢¢ountlng Gonv•ntlon
Th8 ftn8ndal 8tatsment8 have bogn prepwed In accordanca tho chorfty8 tgmmlng douJment]. th
Ch8rlUes AGI 2011. FRS 102 Tr Flnandal Reporung Stsndard aP￿ICable In th• UK and Rgpubllc ol
Iroland. ('FRS 102.1 and the Ch8rltle8 SORP 'Ae¢ountlng and Reporlng by Chorltle8: Statement ol
Rowmmgndod pract1￿ appllcfi￿e to chadl186 p￿pa￿fig tholr accounts In ac<x)rdane4J vAth tho Fln8ndal
Reportlng Slandard appllcable In the UK ond R¢publl¢ ol Ireland IFRS 102r (off•ctfv8 1 Jonuory 2019). Th•
¢hadty18 a Publlc B•nfrflt EnW as deflnod by FRS 102.
The ¢haty ha8 tak•n advantagg of ts pth81on• In th• SORP for ¢harM88 not to pr•porn o Statun•nt of
Ca8h Flo￿.
Tho ffnandal 8tatemont8 hav• d8part•d from ts CharfU•8 {A￿oUnts and R•port8) Regulallon8 2008 onty to
the extent requlrod to provldo a truo and falr vlow. Th15 dgparturo ha8 Involved followlng the $ts1omonl ol
R8￿mmended Practt¢o for ¢hadlt08 8pptylng FRS 102 rather than th• vernlon ol Iho St•tom•nt of
R0￿mManded Prad¢• whl¢h16 rolerred to In th• Rogulatk*ns but whlch 8lnce been wlthdrawn.
Tho IlDand•l 818tom•nt8 aro pr•pared In 8t8rllng, whlch 1$ the funellon•l ¢Uff•n¢y of the tharfty. Mon•t4ry
amount• In th¢80 Itnan¢lal atat•monl8 rounded to the n•4re8t £.
Tho finandal 8tat•monts have bo•n pr•p•r•J wd•r thfr hlbtorfcal ca)•t c4)nv•nllon.Tho prfndp•l acctyJnllnq
pollcl88 adopted ere 8et out below.
IA Qolng oonc•rn
At tha tlmo of appm%rfng the flnandal thl•m•nl8, th• Iru•tots ha￿ 8 rnaaonable oxp•cthn that tw h
adgqualfj rnsource8 to conllnufj oparafjonal ox1$tsn￿ for the foreseeable futuro. Thu8 ttw conilnue to
adopt thg gobng a)n￿rn basls of a¢counttng In pro￿rIng the ilnanclal 8tatsmants.
la Ch•rlt•bl• fvnd•
Unr88tddod fund8 4rn 8valhbh lor UB• at ts d•cretlon of lh• tr￿t0•S In fw1horanL* of tholr tharftabl•
obloctlv••.
Rgfjtrk￿ fund8 wo 8ubJo¢t to 8p•dft¢ ¢ondlttono by doMr8 88 to th•y m•y be ￿8￿. Thg purpws and
U8e8 of re8trktod fvnd8 aro ¥•t out In the not08 to the flnanclal 8tatemenl8.
End¢Jwrnont funds ore 8ublg¢t lo opKlflc (￿nd￿lon9 by donorn trtal the capltal mu61 be mah)talned ty th•
charfty.
1A Incom•
In￿m910 rgwgn15ed whgn Ihg dwrfty Is18g8lly enthled to It oftor any perfo￿￿n￿o corulAbn6 hove been met,
tho •mounts ¢on bo measured rellabty, and It i• probAblo tho1 In¢omo wlll be re¢olv¢d.
Co8h donatlon8 are r￿QgnISed on recelpL Other don8Uon8 are recognlsed On￿ tho charfty h#8 b88n notffl8d
of the donallon. unle88 perfomwnce con￿￿On9 rnqulre deferral of the amounL In￿rne tax recoverable In
rel•tlon lo donation6 recelved undar G5ftAld or de8d8 of o)Von•nt Is rery)gnkggd at the dme of the dortakn.
Legad88 are r8cognl8od on recglpt OT othenv18e 11 thg charfty haB beon noufted of on Impwdng d&trlbutkM),
th8 amount 18 known. and receipt 18 expgdod. If the emounl 18 not known. Ihe 1ogaLy 18 tr8at6d 86 a
Itlnggnt a880t.

CURE CANCER
UCL CANCER INSTITUTE
NOTES TO THE FINANCIAL STATEME￿￿ (CONTINUED>
FOR THE YEAR ENDED 31 MARCH 2025
A¢¢wntlng poll¢l88
(Contln
1.5 Expend￿r•
Ewenditure is reLwnSsed once there Is a logal or 0)nStn￿¥9 obllgauon to transfor ocoftomlc benefft to
thlftl paty,11 Is probable that a transfer of économlc b￿fft8 wlll be rnqulrod In settlemgn( and the amount of
tho obllgath)n ¢an bg m98gured rellably.
Exp•)dltur• Is dassffied by ac￿￿ty. The costs ol each acuvlty are made up of tha tot81 of dIr￿t costs 8nd
shared Gosts. indudlng support costs Involved In und¢rtaking each actlvlty. Olrect costs attrfbLrtatAe to a stngle
aCts￿ty 8re allocated threclly to that acllvlty. Sh8r8d rxists whlch conldbute to more than ona acbvlty and
support o)sts whlch arg not 8ttrlbulable to a glngla actlvjty are apporlongd belween those actlv1ts8 on a ba818
¢on$istsnt the use of resources. Contral stsff costs are allocatad on th8 basls of 8pont. and
d8pradallon charg88 arg allocated on the poruon of th6 ass•t'$ u88,
1.6 Caih and wh oqulvthnt8
Cash ar¢d cash equivalgrts includo cash In tr&ond. depostt8 hetd at ¢all wlth banks. other S￿￿terrn Ilquld
Investments orfglnal matyriYo$ of month8 or le88. and bank ovordrafts. Bank o￿l￿raft$ are 8hrNm
y￿thin bOrrov￿ngS In current lièbllitl¢s.
1.7 FInan¢1￿ In•trumgnts
The c*tarfty h88 818cleO to aPFly tho wovknlorn of Secllon 11 '88sk FlnarKlal Instrum8nt8' and Sectkjn 12
'Olher FlnancAal InStrum￿ts Is¥uo$' Of FRS 102 to all of N8 finandal Inthmgnts.
Flnanclal In8tNments ore remgnlsed In the charlV8 balartce sheot whon the tharlty b8come8 paty to the
contraclual prO￿810n8 of th8 k18trument.
Flnanclal a88ats and Ilabilittas arg 01tsgL wlth the net amour)ts prnsgnted In tho finandal statements. when
thwe Is a legally enforceablé right to $6t off tha rwnlsed amount8 and thor8 ￿ on Intentlon to Sewe on a nat
ba81s or to roallse thè 88681 and th8 Ilablllty stmultaneously.
Baslc fln8nclal a88¢ts. whlch indude debtors and ¢ash and b8nk balances are Initially measured al
tran8aclk)n prfc& indudlng Iransaclion ¢08ts and aro sub8equenty cath$d al amofllsed cost uslng the gffgctlve
Intsrgst method unl8$9 th8 8￿ng&m8nt ryJnstltytss a finandng transactlon, where Ihe tran50Ctton 18
measured at the presanl value of thg fulure receipts dlscounted at a matht r*e of Inter¢st. Flnandal assets
cL￿Illed as recalv8bl• wlthln ono yaar are not amortw.
84slc flnanclalllablUN•s
Baslc flnartctal Ilabllllles. Indudlng crodttors end bank loan8 are Inltl8lly recognlged at tr8nsactlon prlco unless
the arr8ngem8nt con$litul8s a finan¢ing tran8athon, where tha debt Instrumont 16 me8¥uYed at tho pres8nt
value of tha fulure paymants dlscounted at a marf(et rate of Intore8L Flnand81 IlablllUe8 da$8ffied •$ poyablo
vAthln one year arn not 8morbsed.
Dabt Instruments aro 8ubsequgnUy ￿1rted at amortlsed c<¥il. ualng the effecuvo Intsr8St rate rne1￿d.
Trade credltors are obllgallons to pay for goods or sery1￿$ that havo b8en acqulred tn tho ordlnary COU￿ of
opor8tlon8 from SUFpllers. thounts payablo ar8 dassffied as ujrrent IFablllUe8 tf paymènt 1$ du? wrthln on•
ygar or less. If no( they are presented as nonw¢urront liablllUg8. Trade credIt￿5 arg recogni88d Inlllally at
tran8a¢fjon prf¢e and 8ubsequ9nty me8surod at amortlsod o)st uslng tho effe¢Uv8 Intorest mgthod.
D¢rn¢ognltlon of ffn•nclal Ilabllllle8
Financlal Ilabllldes a￿ d$re￿gnISed when the tharws contradual obllgatlorffj explre ¢y are d18thargod or
•ncelled.

CURE CANCER @ UCL CANCER INSTITUTE
NOTES TO THE FINANCIAL STATEMENT8 {CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
¢rttl￿1 a¢¢ountlng •stlmato0 and Judg•m•nts
In the applEcaUon of the charW$ accAiunllng pomdes. the arn rwulrod to mok8 ludgemenis. eBtlmates
and a88umptlons about the c4rrylng amount of a850ts and118bllltta$ that ora not readlty apparnnt from oth•r
8¢yJrce& The 08dmate8 and 888oclatsd a88umptson¥ are ba8ad on hl8tortcal oxporfence and other f8ctor8 that
are con8ldered to be relovant. Adu81 fe8uIts may dlffer from the8a 08tlmato&
Th• e8ttm81•8 and undorfylng a88umptbM are r•v1¢￿d on an ongolng ba6L8. R&vl8hn8 lo accounllno
98IMat￿ ar6 recognl88d In th8 pwlod In whlch the 08tlmata 18 wh•M th• rnv181on affacts LY¢ly that
pedod, or h lh8 parfod of tho revl8lon and future pgrfod8 the rovl8k>n affe¢ts th)th cuTh•nt and fvlure
p•rlod8.
Oonallon$ l•94cl
lund•
fund•
2026
2024
Donalton8 and g1ft8
Grants #nd glft ald d￿m&
3,804
4,579
8,914
8,183
7,180
Charftsbl• a¢tlvlll••
Total tsnd• Tothl lund8
2026
2024
Tl¢ket $81
Othfjr Inr4yn•
Evonl In¢om&
18.706
1,721
31,640
31,540
18.426
Analys1• by fund
Uftre8trlcted funds
31,640
17.4
1.000

CURE CANCER
UCL CANCER INSTITUTE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
Invg•tm•nts
Unr•strlcted UnrnBtrlotgd
fund•
2025
21)24
Interest receivable
1,244
Charflablo a¢llvllles
Support ol UCL C4n¢•r In8lllu
Funds
2025
Funds
2024
VeroJ8 Htre
Event producuon costg
Gon¢ral ¢xpan6e8
Stal£on¢ry
Independant examlnalion
Donatlon to UGL
4.710
4,635
2,476
147
1,000
85.000
76
95,492
95,492
6.582
And￿kn by lund
Unrostttted lund8
Re8tr1ctgd funds
95,492
5.582
1,000
During tha finanaal ygar, thg thaiity madg a donauon of£8S.000 to support a re8earch pmlo¢t18d by a d¢xtor
afflllaied wllh the UCL CarK•r In$￿tUla. Thg donayon wa8 8pgclftcally deS￿nated to advanco on¢6r re86arch
in Ilne with tho charit￿¥ obiectrrfes.
Tfuot¢
Durfng Ihe year. no truste95 rocfjlved any remuneratlon or other banefits (2024: £NIL).
Ourtng Ihg year ended 31 March 2025. no 8ypon888 havo tjegn InvThd (2024.. £NIL).
The average monthly number Ofern￿oYe8S durlng tho year was:
2025
NumlJ•r
2024
-10-

CURE CANCER
UCL CANCER INSTITUTE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
efflploy•g8
(ContIn￿d)
¢harlly hao no amploye88 and Sts only Koy managemont por80rn01 are th• tru8te8B {2024. tho sam•
Tax•tlon
The chadty Is oxempt from tax on Ints)mo and gdni fallkng wlthln ￿CtIOn 505 of tho T￿sACt 1988 orfj•cllon
202 of th• Taxallonof Chargoablo Galn8 Act 1992 to th• •xMt that th•80 am appllad to It8 charftabl• otyec
10 ￿1)1•1•
Amount• IAlllno dufr wlthln on• y•ar.
Pr•paymonts and lax reco¥8r#bl8
187
11 Cr•dltorn: amounts falllng duo wlthln ono y••r
Accwolj ond def•rr•d tnMm•
1,¢X)O
1.480
12 R•lat•d party tran•a¢tton•
Thorn ¥￿1• no d18d0￿ble rel•lod wAty tran8a¢llon• durtng tho ￿8T12024- norn),
11